Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
37 studies found for:    "Raynaud Disease"
Show Display Options
RSS Create an RSS feed from your search for:
"Raynaud Disease"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease
Condition: Raynaud's Disease
Intervention: Drug: SLx-2101
2 Completed Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Raynaud's Disease Secondary to Scleroderma;   Raynaud's Disease Secondary to Autoimmune Disease
Intervention: Drug: MQX-503
3 Unknown  A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Raynaud's Disease Secondary to Scleroderma;   Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions: Drug: Nitroglycerin;   Drug: Topical AmphiMatrix
4 Completed Lab Study of MQX-503 in Treatment of Raynaud's
Conditions: Raynaud Disease;   Raynaud Disease Secondary to Scleroderma;   Raynaud Secondary to Other Autoimmune Disease
Intervention: Drug: topical organogel with nitroglycerin
5 Completed Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
Condition: Raynaud's Disease
Intervention: Drug: Topical organogel with nitroglycerin
6 Completed Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
Condition: Raynaud's Disease
Intervention: Drug: Nitroglycerin
7 Completed Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Condition: Raynaud Disease
Intervention: Drug: Tadalafil
8 Active, not recruiting A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Condition: Raynaud's Disease
Intervention: Drug: onabotulinum toxin type-A
9 Completed Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
Conditions: Systemic Sclerosis;   Raynaud Disease
Intervention: Drug: iloprost
10 Unknown  Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
Condition: Raynaud Disease
Interventions: Drug: 0.9% nitroglycerin in TAM cream;   Drug: vehicle cream
11 Recruiting Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
Conditions: Raynaud Disease;   Scleroderma, Systemic
Interventions: Procedure: laser speckle contrast imaging;   Procedure: Cooling
12 Unknown  Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
Condition: Raynaud Disease
Intervention: Drug: Ginkgo biloba extract EGb 761®
13 Active, not recruiting Metabolomic Analysis of Systemic Sclerosis
Conditions: Scleroderma (Limited and Diffuse);   Undifferentiated Connective Tissue Disease;   Raynaud Disease;   Vascular Disease;   Healthy Control Subjects
Intervention: Procedure: - Skin biopsy - Urine sample - Blood sample
14 Completed Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
Condition: Raynaud Disease
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
15 Recruiting Epoxy-eicosatrienoic Acid and Nitrogen Monoxide in Post-occlusive Cutaneous Finger Hyperaemia and the Response to Cold in Primary Raynaud Phenomenon.
Conditions: Raynaud Disease;   Hyperemia;   Cold;   Fluconazole
Interventions: Procedure: post-occlusive hyperemia;   Procedure: cooling box;   Drug: L-NMMA and Fluconazole dermic injection
16 Completed Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Scleroderma;   Autoimmune Diseases
Intervention: Drug: Topical AmphiMatrix with nitroglycerin (MQX-503)
17 Completed Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
Condition: Raynaud's Disease
Intervention: Drug: Pletal
18 Completed PF-00489791 For The Treatment Of Raynaud's
Conditions: Raynaud's Disease;   Peripheral Vascular Disease
Intervention: Drug: PF-00489791
19 Completed Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
Condition: Raynaud's Disease
Intervention: Drug: Pletal
20 Completed St. John's Wort in the Treatment of Raynaud's Phenomenon
Condition: Raynaud's Disease
Interventions: Drug: St. John's Wort;   Drug: Lactose

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Indicates status has not been verified in more than two years